The FDA has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback